Peregrine Capital Management LLC Raises Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Peregrine Capital Management LLC lifted its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 15.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,117 shares of the company’s stock after acquiring an additional 12,793 shares during the quarter. Peregrine Capital Management LLC owned about 0.14% of Structure Therapeutics worth $4,681,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in GPCR. CWM LLC increased its holdings in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Structure Therapeutics by 3.6% during the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after purchasing an additional 320 shares in the last quarter. State of Wyoming lifted its stake in shares of Structure Therapeutics by 29.7% during the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after purchasing an additional 403 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Structure Therapeutics by 9.4% in the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after buying an additional 413 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Structure Therapeutics by 4.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after buying an additional 444 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $52.12 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90. The stock’s 50-day simple moving average is $42.13 and its 200-day simple moving average is $57.59. The firm has a market cap of $3.70 billion, a price-to-earnings ratio of -59.91 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GPCR shares. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Finally, Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.